Vuori Kristiina MD 4

What Happened
Kristiina Vuori, a director of Bionano Genomics (BNGO), received a grant of 9,149 derivative shares reported on 2026-05-14. The Form 4 lists the acquisition price as $0.00 (an award/grant), so no cash was paid. This is an equity award—not an open-market purchase or sale.

Key Details

• Transaction date: 2026-05-14; transaction code: A (award/grant of derivative securities).
• Reported price: $0.00 per share (award); total reported cash value = $0.
• Vesting: Shares vest in equal monthly installments over the 12 months after the grant; will be fully vested by the company’s next annual stockholder meeting subject to Continuous Service, and vest in full upon a Change of Control (per footnote F1).
• Shares owned after transaction: Not specified in the provided Form 4 excerpt.
• Filing timeliness: Reported on the same date (2026-05-14), indicating a timely Form 4 filing.

Context
This was a grant of derivative shares (e.g., restricted stock/RSU-style award as reported) that vest over time, so it does not represent an immediate market purchase or sale. Such awards compensate or retain directors and will convert into owned shares as vesting conditions are met; they do not necessarily indicate near-term trading intentions.